<?xml version="1.0" encoding="UTF-8"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-10-18T23:54:08Z</responseDate><request verb="GetRecord" identifier="oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/12145" metadataPrefix="oai_dc">https://ebyu-rdlopen.rawdatalibrary.net/oai/request</request><GetRecord><record><header><identifier>oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/12145</identifier><datestamp>2026-10-18T21:13:22Z</datestamp><setSpec>openaire</setSpec><setSpec>driver</setSpec><setSpec>com_ebyu_10000</setSpec><setSpec>col_ebyu_10001</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:title>Highlighting selected research conducted in older patients presented at the European Society for Medical Oncology (ESMO) 2022 Congress – a Young International Society of Geriatric Oncology (SIOG) perspective</dc:title><dc:creator>Akagunduz, Baran</dc:creator><dc:creator>Martinez-Cannon, Bertha Alejandra</dc:creator><dc:creator>Mir, Nabiel</dc:creator><dc:creator>Velasco, Rogelio N.</dc:creator><dc:creator>Roy, Mukul</dc:creator><dc:creator>Liposits, Gabor</dc:creator><dc:subject>Cancer</dc:subject><dc:subject>European Society for Medical Oncology</dc:subject><dc:subject>Geriatric oncology</dc:subject><dc:subject>Older adults</dc:subject><dc:subject>Aged</dc:subject><dc:subject>Humans</dc:subject><dc:subject>Medical Oncology</dc:subject><dc:subject>Neoplasms</dc:subject><dc:subject>anthracycline derivative</dc:subject><dc:subject>cabazitaxel</dc:subject><dc:subject>granulocyte colony stimulating factor</dc:subject><dc:subject>prostate specific antigen</dc:subject><dc:subject>breast cancer</dc:subject><dc:subject>cancer adjuvant therapy</dc:subject><dc:subject>cancer hormone therapy</dc:subject><dc:subject>cancer prognosis</dc:subject><dc:subject>cancer recurrence</dc:subject><dc:subject>cancer survival</dc:subject><dc:subject>cognition</dc:subject><dc:subject>cognitive defect</dc:subject><dc:subject>Conference Paper</dc:subject><dc:subject>drug efficacy</dc:subject><dc:subject>drug safety</dc:subject><dc:subject>geriatric assessment</dc:subject><dc:subject>geriatrics</dc:subject><dc:subject>high risk patient</dc:subject><dc:subject>human</dc:subject><dc:subject>intermediate risk patient</dc:subject><dc:subject>metastatic castration resistant prostate cancer</dc:subject><dc:subject>metastatic colorectal cancer</dc:subject><dc:publisher>Elsevier Ltd</dc:publisher><dc:date>2023</dc:date><dc:type>Conference Object</dc:type><dc:identifier>https://rdlopen.rawdatalibrary.net/r/ebyu/12145</dc:identifier><dc:identifier>https://doi.org/10.1016/j.jgo.2022.12.001</dc:identifier><dc:identifier>1879-4068</dc:identifier><dc:language>en</dc:language><dc:relation>Journal of Geriatric Oncology</dc:relation><dc:rights>info:eu-repo/semantics/openAccess</dc:rights><dc:type>info:eu-repo/semantics/conferenceObject</dc:type><dc:identifier>https://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/12145</dc:identifier></oai_dc:dc></metadata></record></GetRecord></OAI-PMH>